[go: up one dir, main page]

EA199900409A1 - Растворимые рецепторы бета-лимфотоксина, антитела против рецепторов лимфотоксина и антитела против лимфотоксиновых лигандов как терапевтические агенты для лечения иммунологических заболеваний - Google Patents

Растворимые рецепторы бета-лимфотоксина, антитела против рецепторов лимфотоксина и антитела против лимфотоксиновых лигандов как терапевтические агенты для лечения иммунологических заболеваний

Info

Publication number
EA199900409A1
EA199900409A1 EA199900409A EA199900409A EA199900409A1 EA 199900409 A1 EA199900409 A1 EA 199900409A1 EA 199900409 A EA199900409 A EA 199900409A EA 199900409 A EA199900409 A EA 199900409A EA 199900409 A1 EA199900409 A1 EA 199900409A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lymphotoxin
antibodies against
receptors
immunology
ligands
Prior art date
Application number
EA199900409A
Other languages
English (en)
Other versions
EA002983B1 (ru
Inventor
Джеффри Браунинг
Паула Сьюзан Хокман
Поль Д. Реннер
Фабьенн МакКэй
Original Assignee
Байоджен, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен, Инк. filed Critical Байоджен, Инк.
Publication of EA199900409A1 publication Critical patent/EA199900409A1/ru
Publication of EA002983B1 publication Critical patent/EA002983B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Композиция и способы, включающие "агенты, блокирующие рецептор β-лимфотоксина", которые блокируют передачу сигналов рецептора β-лимфотоксина и могут быть использованы для изменения иммунологических заболеваний, в частности, вызванных антителами иммунных ответов.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199900409A 1996-10-25 1997-10-24 Способ изменения гуморального иммунного ответа с помощью агентов, блокирующих рецепторы бета-лимфотоксина EA002983B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2906096P 1996-10-25 1996-10-25
PCT/US1997/019436 WO1998017313A2 (en) 1996-10-25 1997-10-24 Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases

Publications (2)

Publication Number Publication Date
EA199900409A1 true EA199900409A1 (ru) 2000-02-28
EA002983B1 EA002983B1 (ru) 2002-12-26

Family

ID=21847003

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900409A EA002983B1 (ru) 1996-10-25 1997-10-24 Способ изменения гуморального иммунного ответа с помощью агентов, блокирующих рецепторы бета-лимфотоксина

Country Status (25)

Country Link
EP (1) EP0954333B1 (ru)
JP (1) JP4299887B2 (ru)
KR (1) KR100584704B1 (ru)
CN (2) CN100382844C (ru)
AT (1) ATE331531T1 (ru)
AU (1) AU726357B2 (ru)
BG (1) BG63565B1 (ru)
BR (1) BR9712670A (ru)
CA (1) CA2269614A1 (ru)
CZ (1) CZ142899A3 (ru)
DE (1) DE69736244T2 (ru)
DK (1) DK0954333T3 (ru)
EA (1) EA002983B1 (ru)
EE (1) EE05213B1 (ru)
ES (1) ES2268727T3 (ru)
HU (1) HU226467B1 (ru)
IL (1) IL129527A (ru)
IS (1) IS5031A (ru)
NO (1) NO328540B1 (ru)
NZ (1) NZ335353A (ru)
PL (1) PL190617B1 (ru)
PT (1) PT954333E (ru)
SK (1) SK55399A3 (ru)
TR (1) TR199901636T2 (ru)
WO (1) WO1998017313A2 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
NZ510560A (en) * 1998-10-09 2003-09-26 Biogen Inc Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
KR20020016852A (ko) * 1999-06-28 2002-03-06 스타르크, 카르크 종양 성장의 억제 방법
DE19939653A1 (de) * 1999-08-13 2001-02-22 Thomas Huenig Verwendung CD28 spezifischer monoklonaler Antikörper zur Herstellung einer pharmazeutischen Zusammensetzung
WO2001079496A2 (en) * 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
ATE365214T1 (de) * 2000-04-12 2007-07-15 Jolla Inst Allergy Immunolog Ligand des zelleintritt-vermittelnden proteins von herpes simplex und methoden zu dessen verwendungen
MXPA05006663A (es) * 2002-12-20 2005-09-30 Biogen Idec Inc Agentes del receptor linfotoxina beta en combinacion con agentes quimioterapeuticos.
US7923011B2 (en) 2006-10-12 2011-04-12 Genentech, Inc. Antibodies to lymphotoxin-alpha
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
KR20090071652A (ko) 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
WO2010136480A1 (en) * 2009-05-28 2010-12-02 Glaxo Group Limited Antigen-binding proteins
WO2019238966A1 (en) * 2018-06-15 2019-12-19 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
KR102360196B1 (ko) 2019-10-30 2022-02-08 주식회사 친환경테크 다용도 시트 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0672143B1 (en) * 1992-12-04 2008-06-04 Biogen Idec MA Inc. Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease

Also Published As

Publication number Publication date
NZ335353A (en) 2000-09-29
SK55399A3 (en) 2000-10-09
AU726357B2 (en) 2000-11-02
TR199901636T2 (xx) 1999-09-21
AU5089698A (en) 1998-05-15
CN100382844C (zh) 2008-04-23
CA2269614A1 (en) 1998-04-30
NO991926D0 (no) 1999-04-22
CN1237910A (zh) 1999-12-08
IL129527A (en) 2006-12-10
NO991926L (no) 1999-06-25
DK0954333T3 (da) 2006-10-23
WO1998017313A3 (en) 1998-07-30
IS5031A (is) 1999-04-21
CZ142899A3 (cs) 1999-07-14
IL129527A0 (en) 2000-02-29
EE05213B1 (et) 2009-10-15
EA002983B1 (ru) 2002-12-26
PT954333E (pt) 2006-10-31
HU226467B1 (en) 2008-12-29
EP0954333A2 (en) 1999-11-10
HUP9904516A2 (hu) 2000-05-28
KR100584704B1 (ko) 2006-05-30
ES2268727T3 (es) 2007-03-16
BR9712670A (pt) 1999-10-19
EE9900146A (et) 1999-12-15
WO1998017313A2 (en) 1998-04-30
BG63565B1 (bg) 2002-05-31
PL190617B1 (pl) 2005-12-30
JP4299887B2 (ja) 2009-07-22
ATE331531T1 (de) 2006-07-15
HK1025500A1 (en) 2000-11-17
NO328540B1 (no) 2010-03-15
DE69736244T2 (de) 2007-05-31
JP2001502697A (ja) 2001-02-27
DE69736244D1 (de) 2006-08-10
BG103416A (en) 2000-01-31
CN101239186A (zh) 2008-08-13
PL332972A1 (en) 1999-10-25
KR20000052800A (ko) 2000-08-25
HUP9904516A3 (en) 2002-09-30
EP0954333B1 (en) 2006-06-28

Similar Documents

Publication Publication Date Title
EA199900409A1 (ru) Растворимые рецепторы бета-лимфотоксина, антитела против рецепторов лимфотоксина и антитела против лимфотоксиновых лигандов как терапевтические агенты для лечения иммунологических заболеваний
CA2355976A1 (en) Vascular endothelial cell growth factor antagonists and uses thereof
ES515177A0 (es) Procedimiento para el tratamiento de inmunoglobulina de suero.
NO963168L (no) Immunstimulatoriske monoklonale antistoffer
AR001811A1 (es) Anticuerpos anti-icam-1 modificados y su uso en eltratamiento de inflamaciones
DK0840616T3 (da) Oplöselige lymfotoksin-beta-receptorer og anti-lymfotoksin-receptorer samt ligandantistoffer som terapeutiske midler til behandling af immunologiske sygdomme
EA199800357A1 (ru) Фармацевтические ангиостатические дипептидные композиции и способы их применения
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
EA200301117A1 (ru) Антитела против vla-1
EA200100780A1 (ru) Антагонисты tweak и рецептора tweak и их использование для лечения иммунологических заболеваний
ATE347565T1 (de) Bispezifischer antikörper zur effektiven behandlung von b-zell lymphomen und zellinien
DK0432249T3 (da) Monoklonale antistoffer over for beta-kæden i leukocytadhæsionsreceptoren, fremgangsmåder til fremstilling af disse antistoffer og anvendelse heraf
FR2382460A1 (fr) Complexe antigene proteine pour bloquer les reactions allergiques
ES2058490T3 (es) Metodo de reducir respuestas de inmunoglobulina e.
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
NO952828D0 (no) Synergiserende blanding med en antagonist-virkning på NK1- og NK2-reseptorer
ATE236650T1 (de) Verfahren zur hemmung der phagozytose
MY107386A (en) Method of preventing or reducing eosinophilia
ATE77243T1 (de) E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom.
FI922551A0 (fi) Foerfarande foer skoetsel av septisk chock.
DE69319341D1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
FI92716C (fi) Uudet monoklonaaliset vasta-aineet IFN-omegalle, niiden valmistusmenetelmät ja niiden käyttö IFN-omegan puhdistamiseen ja osoittamiseen
Kilburn et al. Synergism between immune complexes and serum from tumor-bearing mice in the suppression of mitogen responses
RU2001108716A (ru) Способ лечения лиц, страдающих от сепсиса
EP1723967A3 (en) Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU